<DOC>
	<DOCNO>NCT00751894</DOCNO>
	<brief_summary>Hypothesis : pegfilgrastim 200 µg/kg 12 18 day previous chemotherapy provide efficient stem cell mobilization child malignancy Design : phase 2 study . Judgment criterion : percentage child achieve least 5x10e6 CD34 cell standard apheresis ( le 3 blood volume process</brief_summary>
	<brief_title>Pegfilgrastim Stem Cell Mobilization Children ( Meg-5 )</brief_title>
	<detailed_description>Patients : consecutively refer HSC mobilization . 12 18 day previous chemotherapy . No haematological growth factor 8 previous day . Mobilization : one sc injection 200 µg/kg pegfilgrastim ( Neulasta , Amgen ) Evaluation study : CD34 circulate cell day 3 day 7 ; AE record Judgment criterion : percentage child achieve least 5x10e6 CD34 cell standard apheresis ( le 3 blood volume process ) Analysis : sequential Bayesian study</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>0 18 year solid malignancy Lansky score &gt; 70 % 12 18 day since begin last chemotherapy cycle administration hematopoietic growth factor previous 8 day clinical biological condition preclude mobilization collection procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Children</keyword>
	<keyword>cancer</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>Stem cell mobilization</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Children solid malignancy</keyword>
</DOC>